Slow & Steady, page-11

Just out on news.com the same as Pop Pandas post but also added:

The Merck phase III trial using just Keytruda as the first-line treatment for locally advanced or metastatic non-small cell lung cancer resulted in longer overall survival among patients, compared to chemotherapy treatment.
Merck is involved in more than 700 trials evaluating Keytruda as a treatment for a wide variety of cancers, either as a stand-alone treatment or in conjunction with other drugs or treatments.
In March, Immutep shares jumped more than 16 per cent when it announced its collaboration with Merck.
Immutep said at the time that the trial of the combined drugs could lead to more rapid drug development subject to successful outcomes.
The phase II trial of up to 120 patients is expected to start in the second half of 2018 in medical centres in Europe and the US.